Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960854 · ClinicalTrials.gov registry record · Phase 1
A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.
A Phase 1 study of Severe Sepsis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 16
- Study locations
NCT02960854: Completed Phase 1 study of Severe Sepsis, sponsored by Bristol-Myers Squibb.
NCT02960854 is a Phase 1 study of Severe Sepsis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 38 participants, below the 6,207-participant average among 9 other Severe Sepsis trials with a reported enrollment target (99% lower). The trial reports 16 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02960854, a Phase 1 study of Severe Sepsis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 16
- Study locations
Study Summary
A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
Study Locations (16)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center (BIDMC) - Boston
- Baystate Medical Center - Springfield
Colorado
- Univ. Of Colorado Health - Colorado Springs
- Denver Health Medical Center - Denver
California
- Uc Davis Medical Center - Sacramento
Florida
- University Of Florida - Gainesville
Georgia
- Pulmonary And Critical Care Of Atlanta - Atlanta
Illinois
- Osf Saint Francis Medical Center - Peoria
Kentucky
- University Of Kentucky - Lexington
Michigan
- University of Michigan, Division of Acute Care Surgery - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-12-07 |
| Est. Completion | 2018-01-05 |
| Phase | Phase 1 |
What the finished NCT02960854 record still lists
NCT02960854 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 6,207-participant average among 9 other Severe Sepsis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Severe Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.
NCT02960854 lists 16 locations in 13 states (Massachusetts, Colorado, California).
Frequently Asked Questions
What is clinical trial NCT02960854 about?
NCT02960854 is a clinical study titled "A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.". A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.
What is the current status of trial NCT02960854?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2016-12-07. Estimated completion is 2018-01-05.
What conditions does trial NCT02960854 study?
This clinical trial studies the following conditions: Severe Sepsis.
What interventions are being tested in trial NCT02960854?
The interventions under investigation include: Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02960854?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02960854 being conducted?
This trial has 16 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02960854's enrollment target sits among peer trials
38 10th of 9 the lowest of 9 other Severe Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Severe Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zinc Therapy in Critical Illness
ACTIVE NOT RECRUITING · Phase 1
-
Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia
ACTIVE NOT RECRUITING
-
Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock
COMPLETED
-
Predictive algoRithm for EValuation and Intervention in SEpsis
COMPLETED · NA
-
Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)
COMPLETED · Phase 2
-
Ultrasound Measurement of Reactive Hyperemia in Critical Care
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI